Sector Update: Healthcare


Shutterstock photo

Healthcare shares are mixed in pre-market. In stocks news, EnteroMedics ( ETRM ), which is developing medical devices using neuroblocking technology to treat obesity and metabolic diseases, said it believes it remains on track for a decision from the U.S. Food and Drug Administration on its Maestro Rechargeable System in the first half of next year.

ETRM is up more than 3% pre-market, though remain near the bottom of their 52-week range of $0.81 - $4.14.

And, Teva Pharmaceutical Industries Ltd. ( TEVA ) announced the launch of the generic equivalent to ADENOSCAN (adenosine injection) in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.

Marketed by Astellas Pharma, ADENOSCAN had annual sales of approximately $65 million in the United States as of June 30, 2013. TEVA edged up by $0.10 to $38.11 in pre-market trade.

Finally, Sanofi ( SNY ) reports new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia, when added to basal insulin, were greatest in patients with type 2 diabetes who had well-controlled baseline fasting plasma glucose.

These findings are consistent with the efficacy profile of Lyxumia, which shows a clinical and statistically significant reduction in HbA1c across different patient populations. SNY is up 0.40% at $50.64.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing , Commodities
More Headlines for: ETRM , SNY , TEVA

More from MT Newswires


MT Newswires

MT Newswires

Market News, Commodities
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by